linjc16/ctgov huggingface dataset:
Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma

Study Overview
=================
Brief Summary
-----------------
Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC). Through the previous work investigators found that the p53 codon72 (Pro/Arg) was related to the prognosis of NPC; Using the method of proteomics, investigators discovered glycolysis related gene such as PGK1, ALDOA，was associated with radiosensitivity.Thus,with all the previous work,investigators hypothesize that the key gene polymorphisms in glycolytic pathway, such as p53 , influence the glycolytic pathway,which leads to differences in radiosensitivity of NPC. This projects will include 600 cases of patients with NPC to detect common glycolytic key genes polymorphisms. Besides,investigators correlate these factors with their radiosensitivity and prognosis.Then, prediction model will be established, and validation of the prediction model will be done. Using enzyme-labeling instrument ，comet assay and clonogenic assay，cytological experiments will further investigate the influence of key gene polymorphisms on the glycolysis efficiency and mechanism of radiation sensitivity.Thus,investigators could provide theoretical basis of individualized treatment for NPC.

Conditions
-----------------
Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms, Radiosensitivity

Intervention / Treatment
-----------------
* Other: validation group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pathological identified NPC KPS≥70 tolerable and agree for IMRT and concurrent chemotherapy without severe other diseases informed consent Exclusion Criteria: reject treatment cannot tolerate the treatment distant metastasis before treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| training group<br> | Other: validation group<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | up to 60 months |
Evaluation of Eflornithine on Facial and Forearm Skin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms

Official Title
-----------------
A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair

Conditions
-----------------
Hirsutism

Intervention / Treatment
-----------------
* Drug: Eflornithine hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female subjects with clinical diagnosis of facial hirsutism/excessive facial hair Women of childbearing potential must agree to use an effective form of birth control for the duration of the study Skin type I-IV Customary frequency of removal of facial hair two or more times per week Exclusion Criteria: Pregnant or lactating women Severe inflammatory acne or presence of significant scarring on the face History of skin malignancy Connective tissue disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Eflornithine hydrochloride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in facial skin thickness measured by ultrasound at 24 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin biopsies |  |  | 
| Histology and histochemistry in the dermis |  |  | 
| Physician Global Assessment |  |  | 
| Subject Self-Assessment Questionnaire |  |  |
Wheelchair Positioning and Pain in Neuromuscular Patients

Study Overview
=================
Brief Summary
-----------------
A retrospective study with the patients having a positioning consultation at hospital, between 2009 and 2014. In every neuromuscular disorder, the investigators describe the population seen in consultation, the aim of consultation, the postural problem observed in wheelchair, pain when sitting in wheelchair, and pressure ulcer.

Detailed Description
-----------------
Postural problem is described with MCPAA (Measure of Postural Control in Sitting Position, created by B. GAGNON, physiotherapist in Quebec) : we look at pelvic obliquity, pelvic rotation, pelvic anteversion or retroversion, trunk slope and rotation, kyphotic or scoliotic posture, neck posture and legs posture. We evaluate if these deformities are soft, moderate or severe, and if they are relievable

Official Title
-----------------
Assessment of Wheelchair Positioning and Pain in Adults Patients With Neuromuscular Disorder

Conditions
-----------------
Adult Patients With Neuromuscular Disorders Using Wheelchair

Intervention / Treatment
-----------------
* Other: Positioning consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient with neuromuscular disorder using wheelchair Patient having a positioning consultation in GARCHES Hospital Exclusion Criteria: refusal to participate to the protocol pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| neuromuscular patients<br>neuromuscular patients using wheelchair | Other: Positioning consultation<br>* Assessment of pain,bedsores and postural troubles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postural disorders |  | 2h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient with Pain |  | 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuromuscular, Wheelchair, Pain, Bedsore, Trouble postural
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.

Official Title
-----------------
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

Conditions
-----------------
Renal Anemia

Intervention / Treatment
-----------------
* Drug: FG2216


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage 3 or 4 chronic kidney disease appropriate hemoglobin levels Exclusion Criteria: Neovascular age related macular degeneration requiring treatment Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment Any history of malignancy Therapy with recombinant erythropoietin or red blood cell transfusion within 4 weeks Renal Transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: FG2216|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin (Hb) response |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attainment of Hb target range (11-13) |  |  | 
| Duration of maintenance of Hb in target range (11-13) |  |  | 
| Safety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal Anemia, Renal Failure, Kidney Disease, Human EPO
Study Evaluating the Effect of Lecozotan SR on the QTc Interval

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, placebo- and moxifloxacin (open-label)-controlled, 4-period crossover study.

Official Title
-----------------
A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects

Conditions
-----------------
Alzheimer Disease, Healthy

Intervention / Treatment
-----------------
* Drug: Lecozotan SR
* Drug: Moxifloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women and men aged 18 to 55 years inclusive. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion Criteria: History of any clinically important drug allergy. Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lecozotan SR|nan|
|Drug: Moxifloxacin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the effect of drug administration on QTc interval. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy Subjects
Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair

Study Overview
=================
Brief Summary
-----------------
The objective this study is to collect post-market data on the performance of the Zenapro™ Hybrid Hernia Repair Device when used to reinforce or bridge the abdominal wall for the repair of ventral hernias.

Official Title
-----------------
Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair

Conditions
-----------------
Ventral Hernias

Intervention / Treatment
-----------------
* Device: Zenapro™ Hybrid Hernia Repair Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary or recurrent ventral hernia Need for abdominal wall repair with reinforcement or bridging material to obtain the desired surgical result Exclusion Criteria: Age < 21 (i.e., infants, children) Device intended to be used in an infected wound Known sensitivity to porcine material Pregnant or planning pregnancy in the future Life expectancy of less than 12 months from the date of the index procedure Hernia too large to be covered with a single device with at least 4-5 cm of tissue overlap on all sides

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Zenapro™ Hybrid Hernia Repair Device<br>Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias. | Device: Zenapro™ Hybrid Hernia Repair Device<br>* Device will be placed during open or laparoscopic hernia repair.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of hernia recurrence |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ventral hernia, Graft repair
Minocycline Treatment for Cystoid Macular Edema

Study Overview
=================
Brief Summary
-----------------
Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Official Title
-----------------
Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema

Conditions
-----------------
Minocycline, Cystoid Macular Edema

Intervention / Treatment
-----------------
* Drug: minocycline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant diagnosed with CME. Participant aged from 18-60 years old. Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria: Participant is allergy to minocycline or tetracyclines. Participant has no contraindications of minocycline or tetracyclines. Participant has an abnormal function of liver, heart, kidney and thyroid. Female that is pregnant, breast-feeding or planning to become pregnant. Participant that is currently using other medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: minocycline<br> | Drug: minocycline<br>* minocycline capsule (100mg) per day orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of cystoid macular edema | Change of CME measured by Optical coherence tomography (OCT) | At 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of best corrected visual acuity (BCVA) | Change of BCVA measured by the Early Treatment Diabetic Retinopathy Study | At 6 months | 
| Change of macular sensitivity | Change of BCVA measured by Macular Integrity Assessment (MAIA) | At 6 months | 
| Change of retinal vascular leakage | Change of retinal vascular leakage measured by Fundus fluorescein angiography (FFA) or indocyanine green angiography (ICGA) | At 6 months | 
| Change of macular vessel | Change of macular vessel measured by optical coherence tomography angiography (OCTA) | At 6 months |
Smartphone Flicker Fusion Test for Patients With Optic Disorders.

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to validate a quick, easy-to-use and administer smartphone flicker fusion test. The app (called eyeFusion) can potentially be used to easily and quickly collect critical flicker fusion measurements on patients admitted with optic disorders as part of the clinical care process.

Detailed Description
-----------------
The smartphone app developed is a flicker fusion that presents the subject with a series of stimuli consisting of a flickering pattern of bars above or below a static rectangle. For each stimulus presentation, the user has to tap the region that is flickering. The duration of the app is less than 2 minutes. This study will assess the validity of the test construct in measuring flicker fusion thresholds, and serve as a foundation for further iterative designs of the app and future validation and characterization studies.

Official Title
-----------------
Validation of a Smartphone-Based Flicker Fusion Test

Conditions
-----------------
Scotoma

Intervention / Treatment
-----------------
* Device: eyeFusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Control Age matched 18-80 years of age. Healthy normal controls with no known eye disorders. Exclusion Criteria: Scotoma or any other ocular disorder Inclusion Criteria - Patients Age 18-80 Clinically associated scotoma Exclusion Criteria - Patients -Any other ocular disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: eyeFusion Control Subjects<br>Healthy normal controls with no known eye disorders age 18-80. | Device: eyeFusion<br>* Smartphone app based flicker fusion test.<br>|
| Experimental: eyeFusion Patients<br>Scotoma subjects aged 18-80. | Device: eyeFusion<br>* Smartphone app based flicker fusion test.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Validity of the test construct measuring flicker fusion thresholds. | The smartphone app developed is a flicker fusion that presents the subject with a series of stimuli consisting of a flickering pattern of bars above or below a static rectangle. The study will assess the validity of the test construct in measuring flicker fusion thresholds, and serve as a foundation for further iterative designs of the app and future validation and characterization studies. | 1/1/2020 |
Can Additional Preoperative Skin Cleaning on Face, Neck and Chest With Chlorhexidine Reduce Cutibacterium Acnes Contamination on Sutures in Arthroscopy Rotator Cuff Repair?

Study Overview
=================
Brief Summary
-----------------
The purpose of our study was to investigate whether preoperative skin cleaning on face, neck, and chest with chlorhexidine could reduce suture contamination of C. acnes in arthroscopic rotator cuff repair. We hypothesized that preoperative skin cleaning on face, neck and chest with chlorhexidine can reduce C. acnes contamination on sutures in arthroscopic rotator cuff repair.

Official Title
-----------------
Can Additional Preoperative Skin Cleaning on Face, Neck and Chest With Chlorhexidine Reduce Cutibacterium Acnes Contamination on Sutures in Arthroscopy Rotator Cuff Repair?

Conditions
-----------------
C. Acnes, Arthroscopic Rotator Cuff Repair

Intervention / Treatment
-----------------
* Drug: 2% chlorhexidine gluconate skin cleanser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary arthroscopic rotator cuff repair Exclusion Criteria: younger than 18 years having previous shoulder surgeries or shoulder infection episodes having a history of allergy to chlorhexidine who refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Extended shoulder group<br>2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face | Drug: 2% chlorhexidine gluconate skin cleanser<br>* 2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery<br>|
| Experimental: Shoulder group<br>2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla | Drug: 2% chlorhexidine gluconate skin cleanser<br>* 2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery<br>|
| No Intervention: Control group<br>Skin prepare with soap as usual | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Culture positive | Culture positive for C. acnes from the suture used in the arthroscopy | Within 2 weeks postoperatively |